General
Preferred name
TELBIVUDINE
Synonyms
L-Thymidine ()
NV 02B ()
Epavudine ()
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione ()
LDT-600 ()
Sebivo ()
NV-02B ()
2'-deoxy-l-thymidine ()
LDT600 ()
Tyzeka ()
P&D ID
PD009929
CAS
3424-98-4
Tags
prodrug
natural product
drug
available
Approved by
EMA
FDA
First approval
2006
Drug Status
investigational
approved
Drug indication
Hepatitis B virus infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
15
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
VGSC-DB
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
242.09
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.51
TPSA
104.55
Fraction CSP3
0.6
Chiral centers
3.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Target
Protein P
Reverse Transcriptase
Indication
hepatitis B
MOA
DNA polymerase inhibitor
Therapeutic Class
Antiviral Agents
VGSC Target
Nav1.5
Source data
